You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

July 31, 2024

Vietnam Issues First National Technical Regulation for Health Supplements

Subscribe to Updates

On July 18. 2024, Vietnam’s Ministry of Health issued Circular No. 12/2024/TT-BYT promulgating National Technical Regulation QCVN 20-1:2024/BYT on the limits of contaminants for health supplements (“Circular 12”). The new national technical regulation is the very first relating to health supplements, and is expected to have a great impact on the control of health supplement quality in Vietnam. Circular 12 will take effect on August 1, 2025.

Contents of Circular 12

The new circular prescribes limits of contaminants (heavy metals and microorganisms), testing samples and testing methods, management requirements, and responsibilities of entities manufacturing and trading in health supplements.

Supplemented alcohol products which are declared as health supplements are notably excluded from the scope of the regulation.

Transitional Provisions

Health supplements which (i) have been granted a declaration registration certificate, and (ii) are manufactured before August 1, 2025, are allowed to continue to be imported, traded, and circulated until the expiry date of the product, even if it is not aligned with Circular 12, except when there is food safety warning.

Declaration registration dossiers for health supplements submitted before August 1, 2025, will continue to be handled in accordance with the prevailing regulations at the time of submission.

From August 1, 2025, if a health supplement with a granted declaration registration certificate has a manufacturer’s standard that does not comply with Circular 12, the party manufacturing/trading in the product must adjust the product standard to conform to Circular 12 and notify the authority of this adjustment.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

May 3, 2011
In Thailand, the importation, manufacture, and sale of medicine is governed by the Medicine Act B.E. 2510 (1967). The Act also stipulates the requirements/procedures to apply for a license to import, manufacture, or sell medicine and the duties and obligations with which such license holder must comply. This article provides an overview of the requirements.
Read More
May 3, 2011
Written in a Q&A format, this chapter provides a comprehensive overview of the issues faced by life sciences companies in Thailand. Topics covered include the regulatory framework, manufacturing of medicinal products, clinical trials, marketing restrictions, packaging and labeling requirements, intellectual property issues, and product liability.
Read More
May 3, 2011
Before being marketed in Thailand, a wide variety of products must be registered at the Thai Food and Drug Administration (FDA). These products range from food, food supplements, beverages and medical devices to animal health products, cosmetics, hazardous substances, and all types of pharmaceuticals. Due to the large number of product applications that are filed at the Thai FDA and the stringency of registration requirements, registration timelines—particularly for pharmaceutical products—can be very long.
Read More
April 30, 2011
In recent years, Thailand has seen an increasing number of pharmaceutical patent litigations, launched by drug originators to combat infringing generic products in the market. This article looks at the forces underlying this trend and recommends several legal options to allow drug originators to defend their products against low-price infringing generics.
Read More